Intervention Review

You have free access to this content

Maintenance agonist treatments for opiate-dependent pregnant women

  1. Silvia Minozzi1,*,
  2. Laura Amato1,
  3. Cristina Bellisario2,
  4. Marica Ferri3,
  5. Marina Davoli1

Editorial Group: Cochrane Drugs and Alcohol Group

Published Online: 23 DEC 2013

Assessed as up-to-date: 7 OCT 2013

DOI: 10.1002/14651858.CD006318.pub3


How to Cite

Minozzi S, Amato L, Bellisario C, Ferri M, Davoli M. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD006318. DOI: 10.1002/14651858.CD006318.pub3.

Author Information

  1. 1

    Lazio Regional Health Service, Department of Epidemiology, Rome, Italy

  2. 2

    AO Città della Salute e della Scienza di Torino Via San Francesco da Paola 31, CPO Piemonte, Dipartimento Interaziendale di Prevenzione Secondaria dei Tumori S.C. Epidemiologia dei Tumori, Torino, Italy

  3. 3

    European Monitoring Centre for Drugs and Drug Addiction, Interventions, Best Practice and Scientific Partners, Lisbon, Portugal

*Silvia Minozzi, Department of Epidemiology, Lazio Regional Health Service, Via di Santa Costanza, 53, Rome, 00198, Italy. minozzi.silvia@gmail.com.

Publication History

  1. Publication Status: New search for studies and content updated (conclusions changed)
  2. Published Online: 23 DEC 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 3]
Figure 3. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
[Figure 4]
Figure 4. Forest plot of comparison: 1 Methadone versus buprenorphine, outcome: 1.1 Drop-out.
[Figure 5]
Figure 5. Forest plot of comparison: 1 Methadone versus buprenorphine, outcome: 1.3 Birth weight.
[Figure 6]
Figure 6. Forest plot of comparison: 1 Methadone versus buprenorphine, outcome: 1.4 APGAR score.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Methadone versus buprenorphine, Outcome 1 Drop-out.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Methadone versus buprenorphine, Outcome 2 Use of primary substance.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Methadone versus buprenorphine, Outcome 3 Birth weight.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Methadone versus buprenorphine, Outcome 4 APGAR score.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Methadone versus buprenorphine, Outcome 5 Number treated for NAS.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Methadone versus buprenorphine, Outcome 6 Mean duration of NAS treatment.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Methadone versus buprenorphine, Outcome 7 Length of hospital stay.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Methadone versus buprenorphine, Outcome 8 Total amount of morphine for NAS.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Methadone versus buprenorphine, Outcome 9 Serious AE for the mother.
[Analysis 1.10]
Analysis 1.10. Comparison 1 Methadone versus buprenorphine, Outcome 10 Serious AE for the child.
[Analysis 1.11]
Analysis 1.11. Comparison 1 Methadone versus buprenorphine, Outcome 11 Non-serious AE for the mother.
[Analysis 1.12]
Analysis 1.12. Comparison 1 Methadone versus buprenorphine, Outcome 12 Non-serious AE for the child.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Methadone versus oral slow-release morphine, Outcome 1 Use of substance.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Methadone versus oral slow-release morphine, Outcome 2 Birth weight.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Methadone versus oral slow-release morphine, Outcome 3 NAS mean duration.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Methadone versus oral slow-release morphine, Outcome 4 Nicotine consumption.